Dr Adam Sharps' Team searches for novel therapeutic strategies to prevent the development of treatment resistance and to overcome the progression of cancer.
Dr Adam Sharp is Leader of the Translational Therapeutics Team and Honorary Consultant Medical Oncologist within the Prostate Cancer Targeted Therapies Group and Drug Development Unit at the ICR and The Royal Marsden NHS Foundation Trust.
I am a bioinformatician working in the Cancer Biomarkers and Translational Therapeutics Teams at the Institute of Cancer Research. I work with next generation sequencing data to understand prostate cancer biomarkers in advanced disease. I have a multidisciplinary background in medicinal chemistry and molecular biology, as well as bioinformatics expertise, particularly in transcriptomics, epigenomics, integrative omics and biostatistics.
I am a Higher Scientific Officer in the Translational Therapeutics Team at the ICR. My focus is on leveraging apoptotic pathways to combat therapy resistance and study immunogenic responses. I also support the team in various projects, ranging from AR signalling to protein translation, with an aim to translate novel therapeutic strategies to combat lethal prostate cancer.
I am a Prostate Cancer UK Postdoctoral Travelling Fellow working in the Cancer Biomarkers and Translational Therapeutics teams at Institute of Cancer Research. I am currently focused on developing novel therapeutic strategies, as well as discovering vulnerabilities of advanced prostate cancer, to prevent the development of resistance against drugs currently used in clinical practise to tackle this disease.
I am a Postdoctoral Training Fellow working in the Translational Therapeutics team at the Institute of Cancer Research. My research is focused on the role of mRNA translation in prostate cancer, with a focus on discovering novel therapeutic vulnerabilities of advanced stage disease and to identify resistance mechanisms for drugs that are used in the clinic.
I am a CRUK Clinical Research Training Fellow working in the Translational Therapeutics Team and the Prostate Cancer Targeted Therapies Group at the Institute of Cancer Research and Royal Marsden Hospital. I have an interest in developing novel therapeutic approaches to improve outcomes for men with advanced prostate cancer. My PhD is focused on the pre-clinical development and translation of strategies to target the intrinsic apoptosis pathway.
I am a PhD student in the Translational Therapeutics Team at the ICR. My research project focuses on regulating RNA processing in lethal prostate cancer. I hope to discover new strategies, in order to revert resistance to current therapies that targeting androgen receptor signalling in advanced prostate cancer. With my PhD training I hope to learn more about translating pre-clinical findings to the clinic, and help improve the outcome for men with advanced prostate cancer.